Its ability to promote inflammation and goblet cell dysfunction, as well as its involvement in driving mucosal barrier breakdown, suggests that targeting IL-18 could be a valuable approach for treating colitis [34, 35]. 1 The gene discussed is IL18; the disease is colitis.